187 patents
Page 6 of 10
Utility
Modified Binding Polypeptides for Optimized Drug Conjugation
23 Sep 21
Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided.
Qun Zhou, Sunghae Park, Huawei Qiu, Marie-Priscille Brun, Francis Duffieux
Filed: 26 Feb 21
Utility
Quinazoline Derivatives as VEGF Inhibitors
9 Sep 21
Andrew Peter Thomas, Elaine Sophie Elizabeth Stokes, Laurent Francois Andre Hennequin
Filed: 15 Jan 21
Utility
Sterile Chromatography Resin and Use Thereof In Manufacturing Processes
2 Sep 21
Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation.
Rahul Godawat, Veena Warikoo, Rohan Patil, Konstantin Konstantinov, Venkat Kishore Ryakala
Filed: 14 Jan 21
Utility
Methods and Systems for Processing a Cell Culture
2 Sep 21
Provided herein are methods of processing a cell culture and open circuit filtration systems.
Konstantin Konstantinov, Benjamin Wright, Jin Yin, Marcella Yu, Hang Zhou
Filed: 14 May 21
Utility
Glucosylceramide Synthase Inhibitors
26 Aug 21
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
Filed: 27 Apr 21
Utility
Modified Adeno-associated Viral Capsid Proteins for Ocular Gene Therapy and Methods of Use Thereof
26 Aug 21
Provided herein are modified adeno-associated viral (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, and nucleic acids encoding the capsid proteins.
Amy Frederick, Xiaoying Jin, Lin Liu, Catherine O'Riordan, Jennifer Sullivan
Filed: 29 Jan 21
Utility
SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
19 Aug 21
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
Filed: 21 Dec 20
Utility
Methods for Treating Neurological Symptoms Associated with Lysosomal Storage Diseases
19 Aug 21
Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases.
Nigel Patrick Somerville CRAWFORD, Tanya Zaremba FISCHER
Filed: 3 Feb 21
Utility
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
12 Aug 21
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
Meehyung Cho, Timothy J. Turner, Erik Wallstroem
Filed: 19 Jan 21
Utility
Compositions and Methods for Treating Pompe Disease
12 Aug 21
The present application provides methods of treating Pompe disease such as infantile-onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa.
Kristina AN HAACK, Patrick FINN
Filed: 8 Feb 21
Utility
Intraventricular Enzyme Delivery for Lysosomal Storage Diseases
29 Jul 21
Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease.
James DODGE, Marco A. PASSINI, Lamya SHIHABUDDIN, Seng H. CHENG
Filed: 29 Dec 20
Utility
Aav Vectors for Retinal and CNS Gene Therapy
24 Jun 21
Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan.
Abraham SCARIA, Jennifer SULLIVAN, Lisa M. STANEK, Lamya S. SHIHABUDDIN
Filed: 5 Mar 21
Utility
Methods of Processing a Fluid Including a Recombinant Therapeutic Protein and Use Thereof
10 Jun 21
Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit.
Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
Filed: 19 Feb 21
Utility
Tropomyosin-Related Kinase (TRK) Inhibitors
10 Jun 21
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease.
John L. Kane, JR., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
Filed: 25 Sep 20
Utility
Synthesis of Udp-glucose: N-acylsphingosine Glucosyltransferase Inhibitors
10 Jun 21
Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose:N-acylsphingosine glucosyltransferase.
Bradford H. HIRTH, Craig SIEGEL
Filed: 23 Jul 20
Utility
Bone-Targeting Antibodies
3 Jun 21
Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone.
Huawei Qiu, Sunghae Park, James Stefano
Filed: 23 Oct 20
Utility
Use of CXCR4 Antagonists
3 Jun 21
Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist.
David C. DALE, Gary J. BRIDGER, Frank J. HSU
Filed: 13 Jul 20
Utility
Marker for Acid Sphingomyelinase Disorders and Uses Thereof
3 Jun 21
The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease.
Wei-Lien Chuang, Gerald F. Cox, X. Kate Zhang
Filed: 11 Dec 20
Utility
FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function
20 May 21
Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function.
Clark PAN, Huawei QIU
Filed: 8 Oct 20
Utility
Pharmaceutical Compositions for Treating Acid Sphingomyelinase Deficiency
20 May 21
The present invention provides compositions such as aqueous liquid compositions and lyophilized compositions comprising a recombinant human acid sphingomyelinase.
Mark Yang, Claudia Buser, Bernardo Perez-Ramirez, Grant Trierweiler, Sangeeta Benjwal
Filed: 25 Nov 20